NICE guidance - ertugliflozin as monotherapy or with metformin for treating type 2 diabetes

Last edited 05/2019

NICE guidance regarding Ertigliflozin states (1):

• Ertugliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
  • a dipeptidyl peptidase 4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate
    
    
• Ertugliflozin in a dual-therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:
  • a sulfonylurea is contraindicated or not tolerated or
  • the person is at significant risk of hypoglycaemia or its consequences
    
    
• if patients and their clinicians consider ertugliflozin to be 1 of a range of suitable treatments including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen

For full details then consult the full guideline (1).

Reference:

• NICE (March 2019). Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes